相关实验视频

Updated: Jul 5, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

向HER3以克服NSCLC中的EGFR TKI耐药性

Qiuqiang Chen¹, Gang Jia², Xilin Zhang¹

¹Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China.

Frontiers in immunology

|January 19, 2024

概括

人体表皮生长因子3 (HER3) 在非小细胞肺癌中驱动对表皮生长因子受体氨酸激酶抑制剂 (EGFR TKI) 的耐药性. 通过新疗法向HER3显示出克服这种抗性的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

受体氨酸激酶 (RTK) 在细胞信号传递和癌症发育中至关重要.
皮肤生长因子受体氨酸激酶抑制剂 (EGFR TKIs) 是EGFR突变的高级非小细胞肺癌 (NSCLC) 的标准.
获得对EGFR TKIs的耐药性,通常在10-14个月内,限制了治疗的有效性.

研究的目的:

审查人类表皮生长因子3 (HER3) 在EGFR TKI耐药性中的作用.
突出新兴的针对HER3的治疗策略.
评估将HER3向疗法与EGFRTKI结合的潜力.

主要方法:

文献综述侧重于HER3在EGFR TKI耐药机制中的作用.
对新兴的以HER3为中心的治疗方法的分析:单克隆抗体 (mAbs),TKI和抗体-药物联合体 (ADC).
对组合疗法的初步临床数据的检查.

主要成果:

在NSCLC中,HER3是对EGFRTKI耐药性的重要调解者.
新兴的HER3向疗法,包括mAbs,TKI和ADC正在开发中.
初步数据表明,将HER3特异性治疗与EGFR TKIs结合起来,可以提高耐性NSCLC的客观反应率 (ORR) 和整体存活率 (OS).

结论:

向HER3是克服NSCLC中EGFR TKI耐药性的有希望的策略.
结合治疗HER3特异性药物和EGFR TKIs显示增强了抗瘤作用.
进一步的研究对于优化患者选择和理解耐药机制至关重要.

关键词:

帕特里图马布德鲁克斯泰干 (HER3-DXd) 的使用情况抗体与药物结合剂 (ADCs) 是一种抗体与药物结合剂.皮肤上生长因子受体 (EGFR)人类EGFR3 (HER3) 的人类EGFR3 (HER3)非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.受体氨酸激酶 (RTKs) 的使用.电阻的电阻是指电阻的电阻氨酸激酶抑制剂 (TKI) 的使用

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...